2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
about
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusInterferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-AnalysisHepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antiviralsPoint shear wave elastography method for assessing liver stiffnessEfficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trialThe role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.Metabolic profiling of hepatitis B virus-related hepatocellular carcinoma with diverse differentiation grades.Virus-related liver cirrhosis: molecular basis and therapeutic options.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responseThe frequency and determinants of liver stiffness measurement failure: a retrospective study of "real-life" 38,464 examinations.Update on different aspects of HCV variability: focus on NS5B polymerase.Hepatitis C virus infection in the human immunodeficiency virus infected patient.IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storageCentral portalization correlates with fibrosis but not with risk factors for nonalcoholic steatohepatitis in steatotic chronic hepatitis C.HCV infected prisoners: should they be still considered a difficult to treat population?Minimally invasive local therapies for liver cancerRelationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis.Role of genetic polymorphisms in hepatitis C virus chronic infection.Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C.The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smokingHIV and co-infections.Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patientsFactors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.Ophthalmologic complications of antiviral therapy in hepatitis C treatment.Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients.Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience.Direct-acting antiviral agents in patients with hepatitis C cirrhosis.Identifying newly acquired cases of hepatitis C using surveillance: a literature review.Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVBehavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis CEuropean mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients.Liver Transplantation without Perioperative Transfusions Single-Center Experience Showing Better Early Outcome and Shorter Hospital Stay.
P2860
Q24307721-73785CB1-9D38-4B81-B175-83413C7AB315Q26765752-7263CAE2-CCB3-4946-A773-83EF47B19B79Q26782033-DD32FC58-7BDA-4D30-9530-24776A92DFE1Q30439553-109D6D25-742E-45D9-A99A-B8EF28B3CEB0Q30620900-A0495A5B-4478-46C4-B444-B79A2FEF0A7FQ33365130-9AD89DC4-6062-40C3-9EF2-C74A1B466FC4Q33414386-B4954B3B-11E4-4E44-8DA2-6703E55E816AQ33418303-0C205957-B477-4B88-A182-BD3DA4638124Q33597976-5E606B5B-BCF4-4614-95EF-2B2142D850EAQ33718267-DD978D01-0970-4499-9FEB-DDDEB89E9BA9Q33769085-CF0FD173-9793-4017-9B10-12A1E6AE6268Q34047077-0D5B69B4-008F-4665-A6F9-88CAB69E747BQ34163394-114C943B-AB75-40F4-910E-3AFAE021ED5DQ34168504-98F71BE0-EBAB-4ACD-A21B-53B8109B7ABEQ34255562-B0348701-DC1C-4914-828D-CA430D3CD29DQ34474404-1FB38B4B-1E69-4203-A124-8569907655CEQ34647861-72AAF706-4E2F-4C3D-838E-48754E84E189Q34698082-25E8E801-B03A-49FF-827C-E2599CE4107BQ34941459-D000C549-CE7A-44C9-A264-4C28A26DF366Q34974386-2CA11C12-E027-4F8F-BB93-F38BBC511860Q35197174-F5C4E2A1-6DD9-45E4-BCA1-A00C98EF9B80Q35779058-247B6D47-DDD1-4F19-AE0E-4FB111FA1F95Q36258800-88F4213E-D725-41DE-86CA-3DE7354E0E90Q36259199-E8EB2D02-0408-4B70-BD92-CCF7B32BEEB7Q36723994-C7A079DC-03CA-4676-8E82-B41A133E945AQ36970184-AFDF5DDA-CE30-4007-A112-F5BCB915AD14Q37125237-4EA2E404-2F1D-4EFA-AAF5-55695161A360Q37230823-55AD10A5-84A1-41B7-B713-E4C139E2990EQ37245420-B635674A-84E8-4A9E-85F7-BA63A64521C7Q37378913-40C8B45F-B457-4F99-A9EA-53F54CDF8753Q37532685-6DD91403-C496-4565-A77F-857E0E89616EQ37628461-D0E6E8C4-4EFA-4F2B-9800-17494FEA41BEQ37663921-D592BE19-A861-4650-9190-AB1272B922B5Q38014990-4354D3D5-531B-47D1-8FDE-BF01073209BAQ40053800-A1013B35-A157-4F3E-8FCB-F3859BB395FAQ40228687-DFA14BC6-FB50-47B1-9910-40BBBE9A181DQ40910254-E37C6163-0040-4172-AAD3-ED3CE151DBA0Q41093909-AA48F1D7-6CA4-4747-84FA-22A716BCAE79Q42234661-1A1A03BE-B56B-4BDE-A5DE-75EC61E308FFQ42768344-A309D39F-45DA-4663-A16D-34153E01F63F
P2860
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
2011 European Association of t ...... clinical practice guidelines.
@en
2011 European Association of t ...... clinical practice guidelines.
@nl
type
label
2011 European Association of t ...... clinical practice guidelines.
@en
2011 European Association of t ...... clinical practice guidelines.
@nl
prefLabel
2011 European Association of t ...... clinical practice guidelines.
@en
2011 European Association of t ...... clinical practice guidelines.
@nl
P2860
P1433
P1476
2011 European Association of t ...... clinical practice guidelines.
@en
P2093
European Association of the Study of the Liver
P2860
P356
10.1111/J.1478-3231.2011.02703.X
P478
32 Suppl 1
P577
2012-02-01T00:00:00Z